Human Xtensions

Company Overview

Snapshot

Founded in January 2012, Human Xtensions operates with 11–50 employees and has raised a total of $66M across three funding rounds from seven investors. The company received FDA 510(k) clearance for its HandX system in March 2018, marking a significant regulatory milestone for its smart, electro-mechanically simplified surgical systems.

Business overview

Human Xtensions is a medical robotics company specializing in software-driven devices that extend the human hand's reach during minimally invasive surgery. Its core product, HandX, is a lightweight, hand-held device designed to translate a surgeon’s natural hand motions into complex movements inside the patient, aiming to restore ergonomic positioning and enhance control. The company operates within the Health Tech & Life Sciences sector, specifically targeting the Medical Devices and Medical Treatment & Therapeutics markets, serving healthcare providers globally.

Strategic signal

In October 2023, Human Xtensions signed a distribution agreement with a company in Abu Dhabi, signaling a strategic expansion into new international markets. This move indicates the company's focus on broadening its commercial reach and establishing a stronger global presence for its robotic surgical solutions, which could drive future revenue growth and market penetration.

Company Intelligence Q&A

What is Human Xtensions' primary product?

Human Xtensions' primary product is HandX, a smart, electro-mechanically simplified surgical system designed as a lightweight, hand-held device that translates a surgeon’s natural hand motions into complex movements inside the patient.

When did Human Xtensions receive FDA clearance for HandX?

Human Xtensions received FDA 510(k) clearance for its HandX system in March 2018, allowing it to market the device as the first in a line of smart digital handtop solutions.

What was a significant recent business development for Human Xtensions?

In October 2023, Human Xtensions entered into a distribution agreement with a company based in Abu Dhabi, aiming to expand its market presence in the Middle East.

What was the outcome of Human Xtensions' IPO?

Human Xtensions completed an Initial Public Offering (IPO) on the TASE in December 2020, raising $48M in capital.

What strategic move did Human Xtensions make regarding its US operations?

In April 2023, Human Xtensions announced plans to reduce its activities in the US, with the goal of saving 31% of its expenses.